CSL Research Acceleration

Leading global biotechnology company, CSL, is supporting medical researchers to help turn a scientific discovery into an innovative new medical treatment or technology.  

In a new collaboration initiative that includes Hudson Institute and Monash University, CSL will fund up to three projects across the initiative, awarding up to $250,000 p.a. for up to two years to support development of successful projects.

Scientists from Hudson Institute and Monash University with research suitable for commercialisation in the targeted areas below are invited to attend a CSL information session at Monash University on Tuesday, 2 April. 

THERAPEUTIC AREA	FOCUS AREA	MODALITY
Immunology Haematology Thrombosis Transplant Respiratory Cardiovascular / Metabolic	Novel drug target Clinical sample &/or clinical data collaborations Novel platforms or technologies relevant to CSL Therapeutic Area or Modality Novel delivery strategy  or enhancement for biologic, gene or cell therapy Biomarker(s) of disease New use for CSL pipeline or on-market product	Antibody Protein therapeutic Gene therapy Cell therapy Other

INFORMATION SESSION

12.45 pm – 1.45 pm

Tuesday, 2 April 2019

Lecture Theatre S9, 16 Rainforest Walk, Clayton Campus, Monash University
REGISTER

APPLICATION AND SUBMMISSION PROCESS

Before submitting please contact Hudson Institute, Commercial Manager, Carmela Monger Submit by COB Friday, 3 May

APPLICATION FORM